Replidyne, Inc Earnings Conference Call (Q4 2007)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Feb 26 Calls Today's Calls

Call Details Replidyne, Inc Earnings Conference Call (Q4 2007) Tue, Feb 26, 2008, 4:45 pm Eastern Listen to the archived event audio About Replidyne, Inc (NasdaqGM:RDYN) Replidyne, Inc., a biopharmaceutical company, focuses on discovering, developing, in-licensing, and commercializing anti-infective products. Its products include Faropenem Medoxomil, an oral antibiotic; and REP8839, an anti-infective product, which is in Phase I clinical development for the treatment of skin and wound infections comprising methicillin resistant Staphylococcus aureus. The company’s various forms of faropenem medoxomil include Oral liquid formulation, which has completed Phase II clinical trial for acute otitis media; 300 mg tablet that has completed Phase III clinical trial for acute bacterial sinusitis; and 600 mg tablet, which is in Phase III clinical trial for acute exacerbation of chronic bronchitis. The company also develops assays that identify compounds that inhibit bacterial DNA replication; and products to treat infections in hospital settings caused by Clostridium difficile. It has license agreement with Daiichi Asubio Pharma Co., Ltd. to develop and commercialize various forms of faropenem medoxomil for adult and pediatric use in the United States and Canada. The company was founded in 2000 and is headquartered in Louisville, Colorado. More Info: Quote | Profile | Reports | Research | Msgs | Insider | Financials | Analyst Ratings